Drug Database
LO

Loxosceles Immune F(Ab)2 (Reclusmyn)

✓ Approved

Instituto Bioclon · Polyclonal Antibodies · Polyclonal Antibodies

What is Loxosceles Immune F(Ab)2?

Loxosceles Immune F(Ab)2 is a polyclonal antibodies developed by Instituto Bioclon. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesReclusmyn
CompanyInstituto Bioclon
Drug ClassPolyclonal Antibodies, Antibody
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Instituto Bioclon

Therapeutic Indications

Loxosceles Immune F(Ab)2 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Injury, poisoning and procedural complicationsVenom poisoning✓ Approved

Related Research Articles

PubMedFrontiers in pharmacology2026-07-17

MOG-Ab-associated optic neuritis with concurrent GFAP-Ab positivity following tislelizumab-based treatment: a case report.

Zhang Yinghui Y, Liu Yonghu Y, Xin Hongxia H, Shi Qin Q et al.

To investigate the clinical characteristics and therapeutic management of myelin oligodendrocyte glycoprotein antibody (MOG-Ab)-related optic neuritis (ON), a rare neurological immune-related adverse event (irAE) associated with the programmed death-1 (PD-1) inhibitor tislelizumab. We report a retrospective case of a 48-year-old male patient with extensive-stage small cell lung cancer (ES-SCLC) who developed acute bilateral vision loss after receiving the first dose of tislelizumab combined with chemotherapy. After admission to the neurology department and a systematic clinical evaluation, the patient was found to be positive for both MOG-Ab and glial fibrillary acidic protein antibody (GFAP-Ab). He was ultimately diagnosed with MOG-Ab-associated ON with Concurrent GFAP-Ab Positivity. Following diagnosis, tislelizumab was promptly discontinued. The patient received high-dose methylprednisolone (1,000 mg/d) as initial therapy, followed by sequential tapering combined with rituximab for immunomodulation. This regimen resulted in considerable visual recovery. In subsequent treatment lines, immune checkpoint inhibitors (ICIs) were avoided. This case underscores the potential of PD-1 inhibitors to trigger rare MOG-Ab-associated ON. For such vision-threatening irAEs, early recognition, immediate ICI withdrawal, multidisciplinary collaboration, and aggressive immunosuppressive therapy are essential for reversing neurological impairment and improving outcomes.

PMID 42466004
Read full article →
PubMedMacromolecules2026-07-17

Oxygen-Tolerant Ab Initio Emulsion ATRP Driven by Red or Near-Infrared Light.

Hu Xiaolei X, Liu Kangping K, Matyjaszewski Krzysztof K

Emulsion polymerization technique is widely used as a practical and greener approach to polymer synthesis. However, previous reversible deactivation radical polymerization (RDRP) in heterogeneous systems has mostly focused on microemulsion and miniemulsion, requiring a large amount of surfactant and/or vigorous homogenization. To expand the scope and enhance the practicality of RDRP in emulsion, we demonstrate a highly efficient and O2-tolerant ab initio emulsion atom transfer radical polymerization (ATRP), driven by red or near-infrared (NIR) light. This was facilitated using a water-soluble photocatalyst, methylene blue (MB+), a hydrophilic initiator, and an interfacial ion-pair catalyst. Excitation of MB+ under red/NIR light irradiation enabled efficient photoreduction of the ATRP deactivator and subsequent initiation in the aqueous phase, thereby mediating polymerization via a classic emulsion mechanism. The ab initio emulsion ATRP provided successful synthesis of polymers with controlled molar masses ranging from 10,000 to 600 000 g/mol and low dispersity (1.09 ≤ Đ ≤ 1.29), excellent chain-end fidelity, and facile temporal control.

PMID 42466176
Read full article →
PubMedIranian journal of nursing and midwifery research2026-07-17

Examining the Effect of an Orientation Tour and Aromatherapy on Stress and Depressed Mood in Birthing Parents with Preterm Infants: A Quasi-Experimental Study.

Amzajerdi Azam A, Keshavarz Maryam M, Babaei Elham E, Pezaro Sally S et al.

Hospitalization of infants in the Neonatal Intensive Care Unit (NICU) may result in psychological morbidities, particularly among birthing parents. This study aimed to evaluate the impact of an orientation tour, both with and without orange aromatherapy, on stress levels and depressive symptoms among birthing parents of preterm infants. In this quasi-experimental, single-blind, three-group study, 130 birthing parents with hospitalized preterm infants were placed in two intervention groups and one control group. This study was undertaken in the NICU of Shahid Akbar Abadi Hospital in Tehran, Iran, from 2020 to 2021. Convenience sampling was used. A 30-minute orientation tour was undertaken by two intervention groups: 1) orientation tour only and 2) orientation tour with aromatherapy. Samples in the orientation tour-aromatherapy group additionally inhaled four drops of 2% orange oil. Data analysis was performed using Chi-square, Fisher's exact test, one-way analysis of variance, and repeated measures analysis of variance tests. 24 hours (but not 1 hour) after visiting the NICU, the average scores for depressed mood (F = 8.53, p < 0.001), the PSS (F = 5.437, p = 0.005), infant behavior and appearance (F = 3.611, p = 0.038), and parental role alteration (F = 4.541, p = 0.006) in the two intervention groups were statistically, significantly lower than those in the control group. Orientation tours, regardless of the use of orange aromatherapy, are effective in improving participants' depressive mood and reducing their stress. Consequently, it is recommended that an orientation tour be provided during parents' initial visit to their infants' hospitalization.

PMID 42466279
Read full article →
PubMedAIDS research and therapy2026-07-17

B/F/TAF in people with both HIV-1 and hepatitis B: outcomes from the ALLIANCE open-label extension phase.

Avihingsanon Anchalee A, Leong Chee Loon CL, Hung Chien-Ching CC, Kiertiburanakul Sasisopin S et al.

Data on bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with both HIV-1 and HBV are limited, particularly for treatment-experienced people. ALLIANCE was a randomized, double-blind, active-controlled, phase 3 study of B/F/TAF versus dolutegravir (DTG) + emtricitabine/tenofovir disoproxil fumarate (F/TDF) in treatment-naïve adults with HIV-1 RNA ≥ 500 copies/mL and HBV DNA ≥ 2000 IU/mL. Participants received continuous B/F/TAF through 144 weeks (≥ 96 weeks of blinded treatment plus 48-week optional open-label extension [OLE]) or switched to B/F/TAF after ≥ 96 weeks of DTG + F/TDF through 48 weeks of OLE. Here we report outcomes from the OLE. 121 participants were included in the continuous B/F/TAF group; 89 in the switch group. Median B/F/TAF exposure was 186.4 and 48 weeks, respectively. HIV-1 and HBV suppression rates (missing = excluded) were maintained in both groups (B/F/TAF Week 144: 99.0% and 80.2%; switch OLE Week 48: 95.4% and 86.6%, respectively). Both groups had improved alanine aminotransferase normalization. HBV envelope antigen loss and seroconversion occurred in 44.8% and 29.3%, respectively, of participants receiving continuous B/F/TAF (Week 144) and 17.0% and 12.8% in the switch group (OLE Week 48). HBV surface antigen loss and seroconversion occurred in 22.5% and 15.5% (continuous B/F/TAF), and 4.3% and 0% (switch group) of participants, respectively. One participant (continuous B/F/TAF) discontinued due to study drug-unrelated treatment-emergent adverse event. No treatment-emergent resistance was reported. B/F/TAF was effective in HIV-1 and HBV suppression and well tolerated in treatment-naïve individuals for ≤ 3 years and ≤ 1 year after switching from a TDF-based regimen. Trial registration ClinicalTrials.gov NCT03547908 (first registration 2018-05-24).

PMID 42464361
Read full article →
PubMedInfection2026-07-17

Comparative immunogenicity and safety of PCV15 versus PCV13 for pneumococcal serotypes 22 F and 33 F: a systematic review and meta-analysis with meta-regression.

Abo Zeid Mohamed M, Mohammed Hazem E HE, Abou Elezz Amr M AM, Gadelmawla Ahmed Farid AF et al.

Streptococcus pneumoniae remains a major cause of morbidity and mortality worldwide, particularly among children and older adults. Although 13-valent pneumococcal conjugate vaccine (PCV13) significantly reduced the burden of pneumococcal disease, non-PCV13 serotypes such as 22 F and 33 F continue to cause invasive pneumococcal disease (IPD). PCV15 was developed to address this gap by including serotypes 22 F and 33 F. Following PRISMA guidelines, a comprehensive literature search was conducted across multiple databases through March 2024. Randomized controlled trials (RCTs) comparing PCV15 and PCV13 were included. Primary outcomes included IgG geometric mean concentrations (GMCs) and opsonophagocytic activity geometric mean titers (OPA GMTs) for serotypes 22 F and 33 F. Nineteen RCTs (n = 16,046) were included. PCV15 demonstrated significantly higher immunogenicity than PCV13 for serotypes 22 F and 33 F across most age and dose subgroups. For IgG GMCs, pooled mean differences (MDs) for serotype 22 F were 6.34 (95% CI 5.13-7.56; I²=97%) in infants, 10.09 (95% CI 6.06-14.13; I²=92%) in children, and 3.19 (95% CI 2.01-4.36; I²=96%) in adults. For serotype 33 F, MDs were 2.40 (95% CI 1.52-3.28; I²=99%), 4.27 (95% CI 3.74-4.80; I²=0%), and 6.81 (95% CI 5.10-8.52; I²=93%), respectively. OPA GMTs also favored PCV15 for serotype 22 F after both single-dose (MD = 1.55, 95% CI 0.69-2.41; I²=99%) and three-dose schedules (MD = 1.66, 95% CI 1.24-2.08; I²=87%), while for serotype 33 F, superiority was observed only with three doses (MD = 0.98, 95% CI 0.56-1.39; I²=90%). PCV15 was associated with higher rates of injection-site adverse events (RR = 1.08, 95% CI 1.03-1.11), whereas systemic adverse events were comparable between groups (RR = 1.03, 95% CI 1.00-1.06). Meta-regression identified a significant negative association between age and IgG GMC 22 F (β=-0.061, 95% CI -0.096 to -0.025; p ≤ 0.001). Certainty of evidence ranged from low to moderate according to GRADE assessment, primarily limited by inconsistency across studies. PCV15 demonstrated significantly higher immunogenicity against serotypes 22 F and 33 F than PCV13 across most age and dose subgroups while maintaining a generally comparable safety profile. These findings support the immunogenic advantage of PCV15 for the additional serotypes included in the vaccine; however, studies evaluating clinical effectiveness are needed to determine whether these immunological differences translate into reductions in pneumococcal disease.

PMID 42467175
Read full article →
PubMedMolecular diversity2026-07-17

Computational structural dynamics and immunoinformatic analysis of EIEC IpaH4.5 targeting immunoprophylaxis design against bacillary dysentery.

Sadhukhan Pinkan P, Mahata Nibedita N

Bacillary dysentery continues as a latent global health challenge, mainly affecting infants in developing nations. The lack of a licensed vaccine and spread of antimicrobial resistance, underlines the need for an alternative immunoprophylactic management. The present study was to identify a nasal subunit vaccine candidate against bacillary dysentery. For this, the virulence-associated EIEC IpaH4.5 protein, also conserved across pathogenic Shigella species, was selected as the antigenic source. A 29-mer protective antigenic peptide (PAP) (44TTTENRIQAVRLLKICLDTREPVLNLSLL72) was identified within its N-terminal region, consisted of overlapping two B-cell, one CTL, and seven HTL epitopes. Both, T-cell epitopes were screened for strong HLA-binding potential (IC50 < 500 nM). Screened HTL epitopes positively induced IFN-γ, IL-4, and IL-10 and were non-homologous to human. Epitope clustering underscored the PAP region, having 99.68% world-wide population coverage. The 3D model of EIEC IpaH4.5 was predicted using ab-initio method (c-score: 0.44). Whereas, homology modelling was utilized to model the extracellular human Toll-like receptors (TLR1/2/4/5/6) corresponding to pulmonary macrophages. A 100 ns molecular dynamics simulation revealed a stable RMSD (Backbone) plot with an average fluctuation of 0.92 ± 0.05 nm for IpaH4.5 and TLR 4 complex. MM/PBSA analysis yielded an average ∆G: - 76.65 ± 8.12 kcal/mol, while MM/GBSA analysis produced a value of - 52.40 ± 6.45 kcal/mol, indicating an energetically favourable complex. In-silico immune titers of the IpaH4.5, was seen to activate both humoral and cellular immunity. Finally, in-silico cloning aided theoretical expression feasibility of the EIEC IpaH4.5. However, real-world experimental validation would be needed for evaluating its protective immunogenicity.

PMID 42463610
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Loxosceles Immune F(Ab)2